ClinicalTrials.govpublic full text
Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome
acute myeloid leukemia (aml), myelodysplastic syndrome (mds), acute myeloid leukemia, myelodysplastic syndrome, refractory, relapsed, hypomethylating agents, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 886703
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.